Subjective well-being in early-phase schizophrenia patients using long-acting injectable vs. oral antipsychotic drugs: data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)
Saved in:
| Main Authors: | Anna-Theresa Schulze, Timo Schurr, Fabienne Post, Beatrice Frajo-Apor, Covadonga M. Díaz-Caneja, Walter Wolfgang Fleischhacker, Michael Davidson, Alex Hofer |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
|
| Series: | European Psychiatry |
| Subjects: | |
| Online Access: | https://www.cambridge.org/core/product/identifier/S0924933825100862/type/journal_article |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
by: Montemagni C, et al.
Published: (2016-04-01) -
Comparative Analysis of Time to All-cause Treatment Discontinuation and Rehospitalization among Early-phase Schizophrenia Patients Discharged on Long-acting Injectable Antipsychotics versus Oral Antipsychotics
by: Ta-Chun Lin, et al.
Published: (2025-01-01) -
Two Long-Acting Antipsychotics in a Patient with Treatment-Resistant Schizophrenia: A Case Report
by: Salvatore Cipolla, et al.
Published: (2025-03-01) -
Population Pharmacokinetic Modeling of TV-46000, a Risperidone Long-Acting Subcutaneous Antipsychotic for the Treatment of Patients with Schizophrenia
by: Itay Perlstein, et al.
Published: (2025-03-01) -
The antipsychotics functional index (AFI) in schizophrenia
by: Gabriel-Cristian Marinescu, et al.
Published: (2025-07-01)